Literature DB >> 7916197

The effects of two anti-CD18 antibodies on antigen-induced airway hyperresponsiveness and leukocyte accumulation in the guinea pig.

A A Milne1, P J Piper.   

Abstract

Guinea pigs sensitized to ovalbumin develop airway eosinophilia and bronchial hyperresponsiveness to acetylcholine and histamine 24 h after ovalbumin challenge. We have used two different antibodies to the leukocyte integrin CD18 (R15.7 and 6.5E) to study the link between eosinophilia and the development of bronchial hyperresponsiveness. In this model, both these antibodies reduced, to a similar degree, the number of eosinophils recovered from bronchoalveolar lavage fluid, although the eosinophil numbers in lung tissue were not reduced. However, only R15.7 reduced bronchial hyperresponsiveness. The results suggest that the CD18 integrin is involved in the recruitment of leukocytes to the airways, but increased numbers of eosinophils in lavage fluid are not an essential correlate of bronchial hyperresponsiveness in this model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916197     DOI: 10.1165/ajrcmb.11.3.7916197

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  4 in total

1.  An emerging paradigm shift on the role of leukocyte adhesion molecules.

Authors:  H Rabb; J G Martin
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 2.  Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors.

Authors:  W J Metzger
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia.

Authors:  C Bandeira-Melo; Y Singh; R S Cordeiro; P M e Silva; M A Martins
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.

Authors:  M M Teixeira; A G Rossi; M A Giembycz; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.